Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.44 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581043 | 1.00 | ADORA3 (0.61) | ADORA3ADORA2BADORA2AADORA1METAP2 | |
| SCHEMBL9919008 | 0.88 | ADORA3 (0.64) | ADORA3ADORA2BADORA2AADORA1MAPT | |
| SCHEMBL31709875 | 0.88 | ADORA3 (0.64) | ADORA3ADORA2BADORA2AADORA1MAPT | |
| SCHEMBL9919004 | 0.82 | ADORA3 (0.61) | ADORA3ADORA2BADORA2AADORA1HTR3A | |
| SCHEMBL709045 | 0.81 | FEN1 (0.66) | ADORA3ADORA2BADORA2AADORA1HTR3A | |
| SCHEMBL9919009 | 0.81 | CA9 (0.66) | ADORA3ADORA2BADORA2AADORA1CA9 | |
| SCHEMBL9923021 | 0.81 | ADORA3 (0.59) | ADORA3ADORA2BADORA2AADORA1HTR3A | |
| SCHEMBL12928421 | 0.81 | ADORA3 (0.59) | ADORA3ADORA2BADORA2AADORA1HTR3A | |
| SCHEMBL625508 | 0.80 | MAPT (0.59) | ADORA3ADORA2BADORA2AADORA1METAP2 | |
| SCHEMBL29502169 | 0.80 | MAPT (0.59) | ADORA3ADORA2BADORA2AADORA1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| EP-2678016-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2010046388-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUINOLIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ADORA3 2189/4885ADORA2B 3308/4885ADORA2A 1459/4885 |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | PIK3C3, ERBB3, ERBB2 | ADORA3 1949/4885ADORA2B 2125/4885ADORA2A 1648/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ADORA3 2189/4885ADORA2B 3308/4885ADORA2A 1459/4885 |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | MTOR, PIK3CA, AKT1 | ADORA3 1200/4885ADORA2B 1372/4885ADORA2A 1064/4885 |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, PIK3CA, AKT1 | ADORA3 1419/4885ADORA2B 1579/4885ADORA2A 1340/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ADORA3 2189/4885ADORA2B 3308/4885ADORA2A 1459/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | ADORA3 2664/4885ADORA2B 3104/4885ADORA2A 2585/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | ADORA3 2469/4885ADORA2B 2255/4885ADORA2A 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.